Currently, there are 44.86M common shares owned by the public and among those 21.26M shares have been available to trade.
The company’s stock has a 5-day price change of 47.97% and -21.93% over the past three months. THRD shares are trading -50.53% year to date (YTD), with the 12-month market performance down to -57.51% lower. It has a 12-month low price of $3.18 and touched a high of $16.94 over the same period. THRD has an average intraday trading volume of 618.81K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 41.84%, 37.82%, and -47.62% respectively.
Institutional ownership of Third Harmonic Bio Inc (NASDAQ: THRD) shares accounts for 56.76% of the company’s 44.86M shares outstanding.
It has a market capitalization of $229.56M and a beta (3y monthly) value of 2.27. The earnings-per-share (ttm) stands at -$1.09. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.70% over the week and 4.70% over the month.
Earnings per share for the fiscal year are expected to increase by 8.72%, and -9.05% over the next financial year. EPS should grow at an annualized rate of -0.64% over the next five years, compared to -34.70% over the past 5-year period.
Looking at the support for the THRD, a number of firms have released research notes about the stock. Stifel stated their Hold rating for the stock in a research note on March 28, 2025, with the firm’s price target at $23-$5. Morgan Stanley coverage for the Third Harmonic Bio Inc (THRD) stock in a research note released on February 12, 2025 offered a Equal-Weight rating with a price target of $5. Raymond James was of a view on February 11, 2025 that the stock is Mkt Perform, while Morgan Stanley gave the stock Overweight rating on August 09, 2024, issuing a price target of $12- $20. Stifel on their part issued Buy rating on June 18, 2024.
